Compare BIP & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIP | ROIV |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | Bermuda | United Kingdom |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3B | 15.8B |
| IPO Year | 2008 | N/A |
| Metric | BIP | ROIV |
|---|---|---|
| Price | $36.52 | $22.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $41.25 | $24.31 |
| AVG Volume (30 Days) | 492.7K | ★ 5.9M |
| Earning Date | 01-29-2026 | 02-06-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $22,240,000,000.00 | $20,329,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $741.42 |
| P/E Ratio | $50.34 | ★ N/A |
| Revenue Growth | ★ 8.14 | N/A |
| 52 Week Low | $25.72 | $8.73 |
| 52 Week High | $36.58 | $23.91 |
| Indicator | BIP | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 67.38 | 47.48 |
| Support Level | $34.50 | $22.28 |
| Resistance Level | $35.34 | $23.11 |
| Average True Range (ATR) | 0.70 | 0.67 |
| MACD | 0.20 | -0.15 |
| Stochastic Oscillator | 98.63 | 21.37 |
Brookfield Infrastructure Partners LP is a Bermuda exempted limited partnership that owns and operates quality, long-life assets that generate stable cash flows, by virtue of barriers to entry or other characteristics that tend to appreciate in value over time. It focuses on acquiring infrastructure assets that have low maintenance capital costs and high barriers to entry. The company's segments consist of Utilities, Transport, Midstream, and Data. Geographically, it generates maximum revenue from USA and also has a presence in Australia, Colombia, United Kingdom, Brazil, United States of America, Chile, Peru, and other countries.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.